An interventional study of EEG Neurofeedback in Alcohol Use Disorder (AUD), sponsored by Brigham and Women's Hospital. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This pilot study is testing a short brain training program called neurofeedback in adults with alcohol use disorder. Participants will complete three sessions over about one week. The goal is to learn if this approach is easy to complete, well tolerated, and acceptable to participants. We will also explore whether it is associated with changes in alcohol cravings and drinking.
Alcohol use disorder (AUD) is a common condition, and many individuals do not respond fully to existing treatments. Neurofeedback is a non-invasive method that uses real-time electroencephalography (EEG) signals to provide feedback, allowing individuals to learn to modulate their brain activity.
This pilot study will evaluate a brief EEG-based neurofeedback intervention in adults with AUD. Participants will complete three in-person sessions over approximately one week. During each session, EEG sensors are placed on the scalp to measure brain activity, and participants receive real-time feedback based on these signals.
The neurofeedback protocol targets downregulation of alpha-band activity (8-12 Hz). This approach differs from traditional alpha-theta neurofeedback and is intended to target patterns of brain activity related to attention, inhibitory control, and craving.
The primary aim is to assess feasibility, tolerability, and acceptability. Feasibility will be evaluated through recruitment, retention, and session completion. Tolerability will be assessed by monitoring adverse events, and acceptability will be assessed through participant-reported experience.
Exploratory outcomes will include changes in alcohol craving and alcohol use based on self-report measures. These analyses are exploratory and intended to inform future studies.
1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.
This study's planned enrollment of 10 is below the median of 88 across 1,433 interventional studies indexed under Alcoholism.
Browse Alcoholism studies →Brigham and Women's Hospital is the lead sponsor of 1,270 studies on the registry; 230 are open to participants now.
Of its 117 completed or terminated interventional studies of FDA-regulated products, 65 (56%) have results posted.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Oct 1, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: EEG Neurofeedback
Participants will receive a brief course of EEG-based neurofeedback consisting of three sessions over approximately one week. During each session, scalp electrodes are placed to record brain activity using electroencephalography (EEG). Real-time feedback is provided to guide participants in modulating their brain activity. The neurofeedback protocol targets downregulation of alpha-band activity (8-12 Hz). Training is delivered using a standardized protocol with real-time visual and/or auditory feedback. Each session lasts approximately 20 minutes, with additional time for setup and brief assessments.
Participant retention rate over 1 week
Proportion of participants who complete all study visits
Time frame: one week
Proportion of participants experiencing adverse events during neurofeedback sessions over 1 week
Number and severity of adverse events
Time frame: One week
Proportion of scheduled neurofeedback sessions completed over 1 week
Proportion of scheduled neurofeedback sessions completed
Time frame: One week
Change in alcohol craving (Penn Alcohol Craving Scale [PACS] total score) from baseline to Visit 3 (~1 week)
Alcohol craving will be assessed using the Penn Alcohol Craving Scale (PACS). PACS total scores range from 0 to 30, with higher scores indicating greater alcohol craving. Change in PACS total score from baseline to Visit 3 (\~1 week) will be analyzed.
Time frame: One week
Change in alcohol consumption measured by Timeline Follow-Back (TLFB) from baseline (Visit 1) to post-intervention (Visit 3, ~1 week)
Alcohol consumption will be assessed using the Timeline Follow-Back (TLFB) method. Change in number of standard drinks over the assessment period from baseline to the final visit will be analyzed.
Time frame: One week
Change in Alpha Power During Neurofeedback Training Relative to Pre-Training Resting EEG
Change in absolute EEG alpha-band power (8-12 Hz) at Pz during neurofeedback training compared with the 3-minute pre-training eyes-open resting EEG recording. Alpha power will be assessed during each of the three neurofeedback sessions to characterize alpha suppression during training.
Time frame: During each of the three neurofeedback sessions over approximately 1 week.
Post-Training Alpha Rebound
Change in absolute EEG alpha-band power (8-12 Hz) at Pz between 3-minute eyes-open resting EEG recordings obtained immediately before and after each neurofeedback session. An increase in post-training resting alpha power relative to pre-training is considered evidence consistent with alpha rebound. Relative alpha power will also be explored.
Time frame: Immediately before and after each of the three neurofeedback sessions over approximately 1 week.
No study locations are listed for this record.
Plan to share: No — There is no current plan to make de-identified individual participant data collected in this study available to researchers outside the study team.
Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.
Of 472 non-industry interventional studies with no phase under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 54. This study's planned 12 months is below that.
Counting every sponsor, half of 495 studies reached it within 33 months; a quarter within 17 and three quarters within 52.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: start Aug 2026 → Dec 2026 and primary completion Jul 2027 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Brigham and Women's Hospital →